Literature DB >> 4709269

The lymphocyte response to primary Moloney sarcoma virus tumors in BALB-c mice. Definition of the active subpopulations at different times after infection.

E W Lamon, H Wigzel, E Klein, B Andersson, H M Skurzak.   

Abstract

Adult BALB/c mice were injected with Moloney sarcoma virus (MSV) after which the animals' lymphocytes were examined for activity against Moloney leukemia virus (MLV) antigen-bearing target cells at 5-day intervals for 30 days. Lymphocytes from these animals and appropriately matched controls were fractionated into B cell-deficient (primarily T cells) and T cell-deficient (primarily B cells) subpopulations. Macrophages were removed using iron powder and magnetism. The unfractionated lymphocytes, T cells, and non-T cells were then tested in microcytotoxicity tests. Antigen-specific activity was found in the unfractionated lymphocytes from animals that had not yet developed palpable tumors and from regressor animals. The T cells were active just before tumor development and just after regression; however, by day 30 after virus infection (8-10 days after regression) the T cell subpopulation was much less active. The non-T cell subpopulation was also active before tumor development and soon after regression. However, this activity continued to rise after regression and was highest at 30 days. At day 15 (peak tumor size) neither subpopulation was active. The activity was demonstrated to be specific for the MLV-determined cell surface antigen by testing on control target cells that were MLV antigen negative and by comparison of the inhibitory effects with lymphocytes immune to a nonpertinent antigen as well as normal lymphocytes. The non-T cells were tested for activity before and after removal of macrophages with iron powder and magnetism. Such cells were significantly more active after removal of the macrophages. These data demonstrate specific T cell and non-T cell activity in microcytotoxicity tests with a tumor-specific system and strongly suggest that the non-T cell activity described herein is a B cell function.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4709269      PMCID: PMC2139349          DOI: 10.1084/jem.137.6.1472

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  33 in total

1.  Studies on the mechanism of rejection of tolerated skin homografts and abrogation of immunological tolerance by hyperimmune serum.

Authors:  M Hasek; E Skamene; I Karakoz; J Chutná; K Nouza; J Bubeník; V Sovová; M Nĕmec; J Jonák
Journal:  Folia Biol (Praha)       Date:  1968       Impact factor: 0.906

2.  The cellular immune response to primary sarcomata in rats. II. Abnormal responses of nodes draining the tumour.

Authors:  P Alexander; J Bensted; E J Delorme; J G Hall; J Hodgett
Journal:  Proc R Soc Lond B Biol Sci       Date:  1969-11-18

3.  Immunologic, virologic, and pathologic studies of regression of autochthonous Moloney sarcoma virus-induced tumors in mice.

Authors:  A Fefer; J L McCoy; K Perk; J P Glynn
Journal:  Cancer Res       Date:  1968-08       Impact factor: 12.701

4.  Studies on Murine Sarcoma Virus: antigenic characterization of Murine Sarcoma Virus induced tumor cells.

Authors:  J C Chuat; L Berman; P Gunvén; E Klein
Journal:  Int J Cancer       Date:  1969-07-15       Impact factor: 7.396

5.  An extension of the 51Cr-release assay for the estimation of mouse cytotoxins.

Authors:  W Boyle
Journal:  Transplantation       Date:  1968-09       Impact factor: 4.939

6.  Differential effects of human granulocytes and lymphocytes on human fibroblasts in vitro.

Authors:  G Lundgren; C F Zukoski; G Möller
Journal:  Clin Exp Immunol       Date:  1968-10       Impact factor: 4.330

7.  Evolution of cell-mediated immunity in mice bearing an antigenic tumor. Influence of tumor growth and surgical removal.

Authors:  G Barski; J K Youn
Journal:  J Natl Cancer Inst       Date:  1969-07       Impact factor: 13.506

8.  Evidence for an immunological reaction of the host directed against its own actively growing primary tumor.

Authors:  Z B Mikulska; C Smith; P Alexander
Journal:  J Natl Cancer Inst       Date:  1966-01       Impact factor: 13.506

9.  Red cells coated with immunoglobulin G: binding and sphering by mononuclear cells in man.

Authors:  A F LoBuglio; R S Cotran; J H Jandl
Journal:  Science       Date:  1967-12-22       Impact factor: 47.728

10.  Cell to cell interaction in the immune response. II. The source of hemolysin-forming cells in irradiated mice given bone marrow and thymus or thoracic duct lymphocytes.

Authors:  G F Mitchell; J F Miller
Journal:  J Exp Med       Date:  1968-10-01       Impact factor: 14.307

View more
  28 in total

1.  Effect of radiotherapy on lymphocyte cytotoxicity in vitro.

Authors:  J Wasserman; B Melén; H Blomgren; U Glas; P Perlmann
Journal:  Clin Exp Immunol       Date:  1975-11       Impact factor: 4.330

2.  Bone marrow suppressor B cells in vitro.

Authors:  B B Fuchs; R M Khaitov; R V Petrov; R I Ataullakhanov; I G Sidorovich; L V Vanko; V V Malaitsev
Journal:  Immunology       Date:  1978-12       Impact factor: 7.397

Review 3.  Cell-mediated tumour immunity in patients with transitional cell carcinoma of the urinary bladder.

Authors:  J Bubeník
Journal:  Int Urol Nephrol       Date:  1975       Impact factor: 2.370

4.  Characteristics of complexes for arming and inhibiting effector cells for antibody-dependent cell-mediated cytotoxicity.

Authors:  L Walker; F C Hay; I M Roitt
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

5.  Detection of cytotoxic lymphoid spleen cells from STU-mice with Moloney sarcoma by a 3H-proline microcytotoxicity assay.

Authors:  E Weiland; M Mussgay
Journal:  Med Microbiol Immunol       Date:  1976-06-01       Impact factor: 3.402

6.  Cell-mediated immunity in rubella assayed by cytotoxicity of supernatants from rubella virus-stimulated human lymphocyte cultures.

Authors:  T Vesikari; G Y Kanra; E Buimovici-Klein; L Z Cooper
Journal:  Clin Exp Immunol       Date:  1975-01       Impact factor: 4.330

7.  Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.

Authors:  R N Germain; R M Williams; B Benacerraf
Journal:  Am J Pathol       Date:  1976-12       Impact factor: 4.307

8.  Mechanisms of specific and non-specific tumour immunity after azathioprine treatment of mice.

Authors:  E C Purves
Journal:  Clin Exp Immunol       Date:  1975-11       Impact factor: 4.330

9.  Cell cytotoxicity due to specific influenza antibody production in vitro after recent influenza antigen stimulation.

Authors:  S B Greenberg; H R Six; S Drake; R B Couch
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

10.  Murine T cells that lyse antibody-sensitized target cells. III. Contribution of Thy 1-Bearing cells to the lytic activity of normal spleen.

Authors:  E W Lamon; B A Pollok; A S Walia; E W Fuson; B Williams
Journal:  Immunology       Date:  1981-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.